New drug cocktail could make kidney transplants safer
NCT ID NCT05669001
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This study tested a new combination of drugs—siplizumab plus belatacept and mycophenolic acid—in 76 people who just received a kidney transplant. The goal was to see if this combo is safer and works better than the standard immunosuppression therapy. Researchers measured side effects and kidney function over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Inova Fairfax Hospital Medical Campus
Falls Church, Virginia, 22042, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Tampa General Hospital
Tampa, Florida, 33606, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
University of California San Francisco Medical Center
San Francisco, California, 94143, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Virginia Health
Charlottesville, Virginia, 22903, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siplizumab (TCD601) combined with belatacept and mycophenolic acid
What this could lead to
If successful, this combination could offer a safer and more effective way to prevent organ rejection in kidney transplant recipients, reducing side effects from standard drugs.
What could go wrong
This is a small, early-phase (Phase 2) study with only 76 participants, so results may not apply to everyone. The new combination may not be safer or could cause unexpected side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.